Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Bioterrorism/biowarfare
- CDC priority list of pathogens
- Viruses as BW agents
- Effective viral biothreats
- Biodefense vaccines
- Viral biothreats
- Smallpox description
- Smallpox historical BW threat
- Smallpox eradication
- Smallpox: the disease
- Smallpox: pros as a biothreat
- Smallpox: cons as a biothreat
- CDC vaccination plan for a BT event
- Monkeypox
- Smallpox: live Vaccinia virus vaccines
- Smallpox: MVA (modified Vaccinia virus Ankara)
- Smallpox: vaccines - risk vs. benefit
- Smallpox: therapeutics - cidofovir
- Smallpox: therapeutics - ST-246
- Smallpox - BW/BT considerations
- Equine encephalitis viruses
- VEEV, EEEV, WEEV
- U.S. cases of EEE
- U.S. cases of WEE
- Natural EEEV and WEEV cycles
- Natural VEEV cycles
- VEE outbreaks
- Existing Alphavirus vaccines
- Next generation vaccines
- VEEV, EEEV, WEEV - BW/BT considerations
- Viral hemorrhagic fevers
- Virus families causing VHF
- Viral hemorrhagic fever distribution
- Symptoms of VHF
- Treatment of VHF
- Filoviruses
- VHF as BW agents: Marburg and Ebola viruses
- Filoviruse distribution
- Filoviruse mortality
- Ebola hemorrhagic fever
- Marburg hemorrhagic fever
- Ebola hemorrhagic fever - disease symptoms
- Treatment of filovirus infections
- Stopping a filovirus epidemic
- Filovirus vaccine development
- FHF - BW/BT considerations
- Rift Valley fever virus
- RVF historically exclusive in Africa
- RVF in Saudi Arabia/Yemen 2002
- Correlation of rainfall to outbreaks of RVFV
- RVF ongoing outbreak - Kenya
- RVF - human disease
- Treatment of RVFV
- RVF - animal disease
- Rift valley fever vaccines (1)
- Rift valley fever vaccines (2)
- Rift valley fever vaccines (3)
- Rift Valley fever virus - BW/BT considerations
- Other challenges
- Conclusions
Topics Covered
- Viruses as bioterrorism or biowarfare threats
- Smallpox virus and monkeypox virus
- Equine encephalitis viruses: Venezuelan, eastern and western equine encephalitis viruses
- Ebola and Marburg viruses
- Rift Valley fever virus
- Genetically engineered viruses
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Schmaljohn, C. (2007, October 1). Biodefense challenges [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 21, 2024, from https://doi.org/10.69645/XERH2882.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Connie Schmaljohn has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.